4DMedical (ASX:4DX) making strides in US commercialisation

4DMedical Limited (ASX:4DX) has achieved significant milestones in its commercialisation strategy, particularly in the US market. The company has been granted a US$299 reimbursement benefit for XV LVAS® from the US Centers for Medicare and Medicaid Services (CMS), accelerating the utilization of XV LVAS® under the existing Category III CPT code. Additionally, 4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAST), which enhances the accessibility of functional lung imaging in the US and expedites the commercialization of the CT:VQ technology.

Executive Commentary on Recent Developments

4DMedical is pleased to report the significant progress made in executing our commercialization strategy, particularly in the US market. The recent FDA clearance for our CT-based ventilation product and the reimbursement benefit from the US Centers for Medicare and Medicaid Services (CMS) are key milestones that will accelerate the adoption and utilization of our technology. The acquisition of Imbio further strengthens our position by providing capabilities in lung structure diagnostics, complementing our existing offerings and enabling a comprehensive solution for clinicians. These developments validate our commitment to becoming the standard of care for lung diagnosis, and we are excited about the opportunities ahead.

Summary of Recent Developments and Outlook

4DMedical (ASX:4DX) has made significant strides in its commercialization strategy, particularly in the US market, with the recent FDA clearance for its CT-based ventilation product and the reimbursement benefit from the US Centers for Medicare and Medicaid Services (CMS). The acquisition of Imbio further enhances the company's capabilities in lung structure diagnostics, positioning it to offer a comprehensive solution to clinicians. With a strong outlook, 4DMedical aims to accelerate the adoption of its XV Technology® and expand its market presence, reaffirming its commitment to revolutionizing lung health diagnostics.